This study demonstrated the efficacy of adjuvant atezolizumab for 1 year compared with the best supportive care in patients with pathologic stage II–IIIA NSCLC with PD-L1 TPS ≥ 1% (HR for disease-free survival (DFS): 0.66 [95% CI: 0.50–0.88; p = 0.0039]). The gene discussed is CD274; the disease is non-small cell lung carcinoma.